There are currently 28 active clinical trials seeking participants for Colorectal Neoplasms research studies. The states with the highest number of trials for Colorectal Neoplasms participants are California, Other, Texas and Ohio.
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249
Recruiting
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Massachusetts General Hospital ., Boston, Massachusetts +13 locations
Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
Register for Updates
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT04222413
Recruiting
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs. Objective: To find a safe dose of metarrestin and to see if this dose shrinks tumors. Eligibility: Adults age 18 and older with pancreatic cancer, breast cancer, or a sol... Read More
Gender:
All
Ages:
Between 12 years and 120 years
Trial Updated:
06/20/2024
Locations: University of Kansas, Fairway, Kansas +1 locations
Conditions: Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Register for Updates
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
NCT04976634
Recruiting
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047), Tucson, Arizona +56 locations
Conditions: Carcinoma, Hepatocellular, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma, Biliary Tract Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms
Register for Updates
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
Recruiting
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Palo Verde Cancer Specialists, Glendale, Arizona +220 locations
Conditions: Colorectal Neoplasms
Register for Updates
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209
Recruiting
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of ev... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: UC San Diego / Moores Cancer Center, La Jolla, California +63 locations
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Register for Updates
A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05571839
Recruiting
This study will test the safety of a drug called SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if SGN-BB228 is safe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +18 locations
Conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Register for Updates
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
NCT05185947
Recruiting
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor. Researchers want to test a new treatment. Objective: To learn if the combination of oral nilotinib plus paclitaxel given by IV and directly into the abdomen can reduce tumors enough for people to have surgery. Eligibility: Adults aged 18 and older with peritoneal carcinomatosis that is to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/08/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Appendiceal Cancer, Appendiceal Neoplasms, Gynecologic Cancer, Gynecologic Neoplasms
Register for Updates
Early Detection of Advanced Adenomas and Colorectal Cancer
NCT06342440
Recruiting
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: City of Hope Medical Center, Monrovia, California +5 locations
Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver
Register for Updates
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
NCT01915225
Recruiting
Background: - Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC). Objectives: - To collect tissue samples for use in studying new ways to treat tumors. Eligibility: Adults 18 years and o... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Pancreas Cancer
Register for Updates
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
NCT02484404
Recruiting
Background: - Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is a drug that may stop the blood vessel growth of cancer cells. This study has two components. In the phase 1 component of the study, researchers want to investigate how well participants tolerate the combination of these drugs in treating advanced solid tumors, and in the phase 2 part of this study, resea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colorectal Neoplasms, Breast Neoplasms
Register for Updates
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
NCT05286814
Recruiting
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug M9241 can improve the treatment. The drug triggers the immune system to fight cancer. Objective: To see if treatment with HAIPs to deliver liver-directed chemotherapy in combination with M9241 is effective for certain cancers. Eligibility: People aged 18 and older who have cancer of the bile ducts that is only in the liver,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms
Register for Updates
First in Human Study of AZD9592 in Solid Tumors
NCT05647122
Recruiting
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Research Site, Duarte, California +43 locations
Conditions: Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
Register for Updates